Home » Newsletters » BioWorld Science

BioWorld Science

July 30, 2008

View Archived Issues

HSPA12B, a novel target for antiangiogenesis therapy

Novel monoclonal antibodies show low tendency for bleeding in models of arterial thrombosis

Titan presents positive phase III results for Probuphine in opioid addiction

FDA grants orphan drug designation to Polyphenon's Polyphenon E for CLL

Allergan to initiate phase I clinical development of retargeted endopeptidase drug candidate

CHMP recommends refusal of Santhera's MAA for Sovrima in Friedreich's ataxia

FDA issues not approvable letter in response to Vanda's NDA for iloperidone in schizophrenia

Anticoagulant Xarelto recommended for approval in E.U.; NDA submitted in U.S.

Chinese SFDA approves Nexavar for HCC

No improvement with BioBypass gene therapy in patients with refractory ischemia

A Ginkgo biloba extract improves cognitive and neuropsychiatric symptoms in AD and vascular dementia

Clinical results with bapineuzumab immunotherapy in mild to moderate AD reported at ICAD

GPC Biotech reports withdrawal of MAA for satraplatin in prostate cancer

FDA issues not approvable letter to Eisai for sedative-hypnotic agent fospropofol disodium

SuperArray Bioscience changes name to SABiosciences

Merck & Co places development hold on HIV protease inhibitor PPL-100

CHMP recommends marketing authorization for GSK's prepandemic influenza vaccine

Sanofi pasteur agrees terms of cash offer for share capital of Acambis

Arpida submits MAA to the EMEA for iclaprim in cSSTI

Roche submits application to EMEA to extend label for Avastin in breast cancer

MediGene's Oracea receives marketing authorization in Europe

Nuvelo commences phase I NU-206 trial in healthy volunteers

European Commission approves Schering-Plough's Bridion

Novel antidiabetic agents claimed in recent patents

Advances in development of agents for neurological disorders documented in recent patents

FDA issues not approvable letter to UCB for Vimpat in diabetic neuropathic pain

Novel Rho kinase inhibitors developed at sanofi-aventis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 3, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...